

# AACE/ACE 2020 POSTMENOPAUSAL OSTEOPOROSIS TREATMENT ALGORITHM

Lumbar spine or femoral neck or total hip T-score of  $\leq -2.5$ , a history of fragility fracture, or high FRAX® fracture probability\*

Evaluate for causes of secondary osteoporosis

Correct calcium/vitamin D deficiency and address causes of secondary osteoporosis

- Recommend pharmacologic therapy
- Education on lifestyle measures, fall prevention, benefits and risks of medications

## High risk/no prior fractures\*\*

- Alendronate, denosumab, risedronate, zoledronate\*\*\*
- **Alternate therapy:** Ibandronate, raloxifene

Reassess yearly for response to therapy and fracture risk

Increasing or stable BMD and no fractures

Consider a drug holiday after 5 years of oral and 3 years of IV bisphosphonate therapy

Resume therapy when a fracture occurs, BMD declines beyond LSC, BTM's rise to pretreatment values or patient meets initial treatment criteria

Progression of bone loss or recurrent fractures

- Assess compliance
- Re-evaluate for causes of secondary osteoporosis and factors leading to suboptimal response to therapy

- Switch to injectable antiresorptive if on oral agent
- Switch to abaloparatide, romosozumab, or teriparatide if on injectable antiresorptive or at very high risk of fracture
- Factors leading to suboptimal response

### ABBREVIATIONS GUIDE

BMD – bone mineral density  
LSC – least significant change  
BTM – bone turnover marker

## Very high risk/prior fractures\*\*

- Abaloparatide, denosumab, romosozumab, teriparatide, zoledronate\*\*\*
- Alternate therapy: Alendronate, risedronate

Reassess yearly for response to therapy and fracture risk

Denosumab

Romosozumab for 1 year

Abaloparatide or teriparatide for up to 2 years

Zoledronate

Continue therapy until the patient is no longer high risk and ensure transition with another antiresorptive agent.

Sequential therapy with oral or injectable antiresorptive agent

Sequential therapy with oral or injectable antiresorptive agent

- If stable, continue therapy for 6 years\*\*\*\*
- If progression of bone loss or recurrent fractures, consider switching to abaloparatide, teriparatide or romosozumab

\* 10 year major osteoporotic fracture risk  $\geq 20\%$  or hip fracture risk  $\geq 3\%$ . Non-US countries/regions may have different thresholds.

\*\* Indicators of very high fracture risk in patients with low bone density would include advanced age, frailty, glucocorticoids, very low T scores, or increased fall risk.

\*\*\* Medications are listed alphabetically.

\*\*\*\* Consider a drug holiday after 6 years of IV zoledronate. During the holiday, an anabolic agent or a weaker antiresorptive such as raloxifene could be used.

